Blog
RSS FeedPosted by Michael Wonder on 19 Feb 2018
A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma
13 February 2018 - Australian Government subsidisation of ipilimumab for the treatment of patients with metastatic melanoma was conditional on the ...
Posted by Michael Wonder on 06 Jan 2018
Characteristics of managed entry agreements in Australia
26 December 2017 - Australia relies on managed entry agreements for many medicines added to the national Pharmaceutical Benefits Scheme. ...
Posted by Michael Wonder on 30 Nov 2016
Pharmacies need 6CPA risk share
30 November 2016 - The reason why the Federal Government and community pharmacies have entered into six successive agreements for ...